Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Han R, Ling C, Wang Y, Lu L. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition. Cancer Cell International 2023, 23: 203. PMID: 37716965, PMCID: PMC10504701, DOI: 10.1186/s12935-023-03051-0.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsHepatocellular carcinomaCheckpoint inhibitorsHCC treatmentPD-1/PD-L1 inhibitionPD-1/PD-L1 inhibitorsHDAC2 inhibitorsTreatment of HCCPD-L1 inhibitionAnti-cancer immunityPD-L1 inhibitorsAnti-tumor efficacyNew combination strategiesPD-L1Clinical benefitHigh morbidityTherapeutic effectSolid cancersEffective treatmentLatest evidenceNuclear translocationTreatmentInhibitorsCombination strategiesEfficacyCAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
Han R, Li J, Hony J, Xiao Z, wang J, Yao M, Liang S, Lu L. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Frontiers In Immunology 2023, 14: 1052657. PMID: 37006233, PMCID: PMC10061011, DOI: 10.3389/fimmu.2023.1052657.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsC motif chemokine ligand 8Hepatocellular carcinomaCheckpoint inhibitorsDeath ligand 1 (PD-L1) immunotherapyCell death protein 1Treatment of HCCDeath protein 1Chemokine ligand 8Function of monocytesTumor immunosuppression microenvironmentClinical benefitCombination therapyImmunosuppression microenvironmentLethal malignancyTherapeutic effectEffective treatmentHCC treatmentAdvanced stageProtein 1Ligand 8ImmunotherapyTreatmentXII inhibitorsAnticancer drugs